ATTO (Attovia Therapeutics) PS Ratio: 2,071.50 (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATTO Attovia Therapeutics Inc ATTO
8 GF Score
Price $20.72
! 1 Warning Sign
View Full Analysis

What is Attovia Therapeutics PS Ratio?

Attovia Therapeutics ATTO -6.31% 8 PS Ratio is 2,071.50 as of Sep. 21, 2026. GuruFocus rates ATTO with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 938 Biotechnology companies, Attovia Therapeutics ranks worse than 92.75% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Attovia Therapeutics's share price is $20.715. Attovia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.01. Hence, Attovia Therapeutics's PS Ratio for today is 2,071.50.

The historical rank and industry rank for Attovia Therapeutics's PS Ratio or its related term are showing as below:

ATTO' s PS Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 477.26
Current: 390.66

During the past 2 years, Attovia Therapeutics's highest PS Ratio was 477.26. The lowest was 0.00. And the median was 0.00.

ATTO's PS Ratio is ranked worse than
92.75% of 938 companies
in the Biotechnology industry
Industry Median: 9.375 vs ATTO: 390.66

Attovia Therapeutics's Revenue per Sharefor the three months ended in Jun. 2026 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.01.

Back to Basics: PS Ratio


Attovia Therapeutics  (NAS:ATTO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Attovia Therapeutics PS Ratio Related Terms


Attovia Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Attovia Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Attovia Therapeutics PS Ratio Chart

Attovia Therapeutics Annual Data
Trend Dec24 Dec25
PS Ratio
- -

Attovia Therapeutics Quarterly Data
Mar25 Jun25 Mar26 Jun26
PS Ratio - - - -

ATTO vs TBPH, ACRS, OLMA: PS Ratio Comparison

For the Biotechnology subindustry, Attovia Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Attovia Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Attovia Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Attovia Therapeutics's PS Ratio falls into.


ATTO
8GF Score
Attovia Therapeutics Inc ATTO
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Attovia Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Attovia Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=20.715/0.01
=2,071.50

Attovia Therapeutics's Share Price of today is $20.715.
Attovia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 2,071.50 mean?
Attovia Therapeutics (ATTO) has a PS Ratio of 2,071.50 as of Sep. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Attovia Therapeutics and its competitors. According to the industry distribution chart, Attovia Therapeutics ranks #870 out of 938 companies in the Biotechnology industry, placing it in the top 92.8%.
Is Attovia Therapeutics' PS Ratio too high?
Attovia Therapeutics' current PS Ratio is 2,071.50. The Biotechnology industry median PS Ratio is 9.38. Attovia Therapeutics' value of 2,071.50 is 21996% above this industry median. Based on the distribution chart, Attovia Therapeutics ranks #870 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Attovia Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Attovia Therapeutics' PS Ratio compare to TBPH and ACRS?
According to the Biotechnology industry distribution chart, Attovia Therapeutics ranks #870 out of 938 companies for PS Ratio. This places Attovia Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.38. Attovia Therapeutics' value of 2,071.50 is 21996% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.38, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Attovia Therapeutics's current PS Ratio of 2,071.50 is 21996% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Attovia Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Attovia Therapeutics's current PS Ratio is 2,071.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attovia Therapeutics stock overvalued right now?
Attovia Therapeutics (ATTO) has a current PS Ratio of 2,071.50. The current PS Ratio is 2,071.50 and 21996% above the Biotechnology industry median of 9.38. Attovia Therapeutics' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Attovia Therapeutics (ATTO), the current PS Ratio is 2,071.50 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Attovia Therapeutics Business Description

Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
8GF Score

Get the complete analysis for ATTO

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.72
Price